Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Clay Lies Still, But Blood’s A Rover

    When a drug makes it into the bloodstream (which is no sure thing, on my side of the business), it doesn’t just float around by itself. Blood itself is full of all kinds of stuff, and there are many things in it that can interact with drug molecules. For one thing, compounds can actually wander… Read More
  • Cancer

    Costs and Benefits, Risks and Rewards

    Continuing on the latest issue of the New England Journal of Medicine and its articles on cancer therapies, there’s the Perspective article, from Deborah Schrag at Sloan-Kettering, which points out that: “In the wake of the optimism generated by recent trial results, patients experience sticker shock when they encounter the prices of ch… Read More
  • Business and Markets

    Another Shot Across the Bow

    Since I last wrote about Imclone, the stock has had a rather difficult time. That’s largely the fault of the Imclone fan club: Erbitux sales have exceeded some of the responsible projections, but still haven’t caught up with the fantasies of some of the stockholders. And now comes a study in the New England Journal… Read More
  • Cancer

    Bungee Jumping with PPAR Drugs

    The PPAR family (known in the US as alpha, gamma, and delta, for obscure historical reasons) is one of those biological jungles that keep us all employed. They’re nuclear receptors, and thus they’re involved in up- and down-regulation of hundreds of genes. Like most of the other nuclear receptors, they do that by responding to… Read More
  • Cancer

    It’ll Cost You

    Over at Slate, NBC’s Robert Bazell takes on the drug pricing issue, focusing on the newer oncology therapies. There’s no denying that some of them are really costly, and that this is a situation that probably can’t continue under the current system (which, to exaggerate only slightly, works like this: every cancer patient gets to… Read More
  • Business and Markets

    Vox Populi

    I wasn’t planning on returning to this topic today, but tonight’s e-mail seems to deserve a speedy reply. Says a loyal reader, one “Busterbuckeye”: You gave me a very impolite back hand slap in the above referenced blog. . .(on May 12) I posted in response to your April 28 blog in which you quoted… Read More
  • Business and Markets

    As Goes ASCO. . .

    The American Society of Clinical Oncology meeting is taking place as you read this. ASCO is a pretty high-pressure venue, because key clinical results for cancer therapies are often unveiled there. The audience has a much higher percentage of journalists and financial analysts than you’ll see at most meetings. It’s a sandstorm of hype,… Read More
  • Cancer

    All the Myriad Ways

    Closely related to the patenting of biochemical pathways is the patenting of genes. I’m not completely thrilled with that, either, but it still makes a bit more sense to me. With these patents, you own the gene and uses for it, but you don’t get to claim everything else downstream of it (like the protein… Read More
  • Business and Markets

    Deferred Gratification Is Better Than None At All

    Bad days for Genta and Allos, as the FDA first made their advisory committee minutes public on Friday, then turned down their drug applications yesterday. Both are nominally cancer therapeutics, and both were seen as tests of a supposedly more open attitude at the FDA, but they’re very different situations. Genta is, at first glance… Read More
  • Business and Markets

    Yahoots

    The real news on the cancer front is in the post below, but I have a few other things to take care of tonight, too. Yesterday’s post on Imclone’s stock price was not well-received over on the IMCL message boards on Yahoo, where I’ve picked up several of the usual responses. They include the standard-issue… Read More
...373839...